biotech

biotech Articles

Proteon Therapeutics shares were absolutely crushed on Thursday after the firm announced results from its late-stage trial in patients with chronic kidney disease.
Axsome shares jumped on Wednesday after the firm gave an update from the FDA regarding its AXS-05 for the treatment of major depressive disorder.
The March 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
Curis shares jumped when the firm announced that it entered into an agreement to sell rights to a portion of royalty revenues on worldwide net sales of Erivedge.
Biogen shares made a slight gain early on Monday after the firm made an SEC filing indicating that it will be buying back a sizable amount of stock.
Neurotrope Inc. (NASDAQ: NTRP) may be a winner by default in the battle against Alzheimer’s disease after shares of Biogen Inc. (NASDAQ: BIIB) suffered handily with the announcement that it and...
Biogen shares were crushed in Thursday’s session after the firm announced that it would be discontinuing its late-stage trial for Alzheimer’s disease.
Gene therapy may become the next frontier for drug companies seeking to make billions of dollars improving or even curing certain diseases.
Altimmune shares surged on Tuesday following results from its midstage study of a intranasal influenza vaccine candidate.
Dermira shares more than doubled on Monday after the firm announced midstage results from its Eczema study.
PhaseBio shares more than doubled on Monday after the firm released results from an early-stage clinical trial of its antiplatelet reversal agent.
We screened our 24/7 Wall St. research database and found five biotech stocks trading under the $10 level that could provide investors with some solid upside potential.
Karyopharm shares jumped on Friday after the firm announced an FDA update from the FDA on its treatment for myeloma.
In a new research report, RBC did some intense digging in the small-cap arena and came up with some fascinating research. These are five top small-cap growth plays suited for aggressive accounts.
Patients suffering anemia due to chronic kidney disease are sure to be content with new positive top-line results from two Phase 3 active-controlled pivotal studies.